AZN : Summary for Astrazeneca PLC Common Stock - Yahoo Finance

U.S. Markets close in 4 hrs 28 mins

AstraZeneca PLC (AZN)


NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
30.77+0.19 (+0.64%)
As of 11:32AM EDT. Market open.
People also watch
GSKNVSSNYLLYBMY
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close30.58
Open30.58
Bid0.00 x
Ask0.00 x
Day's Range30.52 - 30.82
52 Week Range25.55 - 35.04
Volume2,011,300
Avg. Volume4,962,977
Market Cap76.3B
Beta0.66
PE Ratio (TTM)22.30
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield1.90 (6.30%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Reuters4 hours ago

    AstraZeneca aims to escape drug sales trough in second half

    AstraZeneca, struggling with loss of patents on blockbusters like cholesterol pill Crestor, reported another quarter of falling drug sales on Thursday as it awaits pivotal clinical trial data that may revive its fortunes. Chief Executive Pascal Soriot believes 2017 will mark the trough for the British group, as it starts to put generic losses behind it and builds up sales of recently launched and experimental cancer medicines. Industry analysts, on average, had forecast revenue of $5.4 billion and earnings of 82 cents, according to Thomson Reuters data.

  • The Wall Street Journal5 hours ago

    [$$] AstraZeneca Profit Drops on Decline in Blockbuster-Drug Revenue

    U.K. drug maker AstraZeneca, battling declining sales of its blockbuster cholesterol pill, posted lower revenue and profit in the first quarter of the year.

  • AstraZeneca Core Earnings Rise Despite Sales Slide; Key I-O Trial Eyed
    Investor's Business Daily6 hours ago

    AstraZeneca Core Earnings Rise Despite Sales Slide; Key I-O Trial Eyed

    The U.K. drug giant reported higher adjusted EPS even as sales continued to fall. AstraZeneca is pinning its hopes on a key immunotherapy drug trial.